A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring CA19-9 levels alone, according to a study published in Clinical Cancer Research.
This article was originally published on MedicalXpress.com

